Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast Cancer
暂无分享,去创建一个
Marion Procter | Thomas Suter | R. Gelber | M. Piccart | J. Baselga | G. Viale | D. Zardavas | G. von Minckwitz | M. Procter | I. Láng | T. Suter | E. de Azambuja | D. Yardley | E. Clark | A. Knott | M. Benyunes | Giuseppe Viale | Martine Piccart | Richard D. Gelber | Gunter von Minckwitz | Jose Baselga | Christelle Levy | Evandro de Azambuja | C. Lévy | Dimitrios Zardavas | Denise A. Yardley | J. Bines | Mark Benyunes | Amal Arahmani | Nathalie Rouchet | Emma Clark | Adam Knott | Istvan Lang | Jose Bines | A. Arahmani | N. Rouchet
[1] D. Amadori,et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. , 2013, The oncologist.
[2] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Reis-Filho,et al. Translating neoadjuvant therapy into survival benefits: one size does not fit all , 2016, Nature Reviews Clinical Oncology.
[4] M. Piccart,et al. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015. , 2015, Breast.
[5] P. Ellis,et al. Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.
[6] Werner Scheuer,et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.
[7] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[8] Paolo Morandi,et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. , 2016, The Lancet. Oncology.
[9] John M S Bartlett,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.
[10] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[11] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[12] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[13] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[14] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.